Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome

T. Fujihara, T. Takeuchi, K. Tsubota, N. Kayagaki, H. Yagita, K. Okumura, T. Abe

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


The aim of the study was to elucidate the involvement of Fas antigen in human autoimmune disease, by analysing serum levels of soluble Fas/APO1 protein in patients with various autoimmune diseases, including system lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), Behcet's syndrome and Sjogren's syndrome (SjS). The levels of soluble Fas/APO-1 in sera were quantitated by a sandwich enzyme-linked immunosorbent assay. Soluble Fas/APO-1 levels were significantly increased in serum from patients with primary Sjogren's syndrome (1°SjS) compared with control subjects. However, no significant differences in soluble Fas/APO-1 levels were noted in patients with secondary Sjogren's syndrome (2°SjS) nor in patients with any of the other autoimmune diseases. The soluble Fas/APO-1 level in 1°SjS patients with extraglandular diseases was significantly higher than that in patients without extraglandular diseases. These results suggest that soluble Fas/APO-1 protein may play an important role in the pathogenesis of 1°SS.

Original languageEnglish
Pages (from-to)496-499
Number of pages4
JournalClinical Rheumatology
Issue number6
Publication statusPublished - 1998
Externally publishedYes


  • Autoimmune disease
  • Enzyme-linked immunosorbent assay
  • Sjogren's syndrome
  • Soluble Fas/APO-1 protein

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome'. Together they form a unique fingerprint.

Cite this